drugset / Trial / NCT00002036

Phase I Safety Study of Anti-HIV Immune Serum Globulin (Human)

NCT00002036

Phase 1 Completed 12 enrolled Abbott
Treatment

Summary

To investigate the potential benefit of providing passive immunity with hyperimmune anti-HIV human serum.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Anti-HIV Immune Serum Globulin (Human) Protein / enzyme biologic